Infectious Disease Molecular Diagnostics Market Report 2026

Infectious Disease Molecular Diagnostics Market Overview

• Infectious Disease Molecular Diagnostics market size has reached to $30.46 billion in 2025 • Expected to grow to $38.77 billion in 2030 at a compound annual growth rate (CAGR) of 4.9% • Growth Driver: The Rise In Infectious Diseases Propels The Growth Of The Market Due To Global Spread And Need For Rapid Diagnosis • Market Trend: Innovative Polymerase Chain Reaction Kits Enhance Speed And Accuracy In Detecting Infectious Pathogens • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Infectious Disease Molecular Diagnostics Market?

Infectious disease molecular diagnostics refers to advanced laboratory techniques used to detect and identify genetic material from pathogens such as bacteria, viruses, fungi, or parasites in patient samples. These diagnostics enable rapid and accurate diagnosis of infectious diseases, supporting timely treatment and effective disease management. The main product types of infectious disease molecular diagnostics are kits and reagents, instruments, software and services. Kits and reagents refer to pre-packaged sets of chemical substances and biological components designed to perform specific laboratory tests or procedures, such as detecting, measuring, or amplifying genetic material, proteins, or pathogens. Key technologies used in this field include polymerase chain reaction, in situ hybridization, isothermal nucleic acid amplification technology, chips and microarrays, mass spectrometry, transcription-mediated amplification, and others. These are used for various applications such as respiratory diseases, tuberculosis, meningitis, gastrointestinal tract infections, human papillomavirus, sexually transmitted infections, sepsis, drug-resistant diseases, and others, and utilized by end users such as hospitals and clinical laboratories, diagnostic laboratories, pharmaceutical companies, and academic and research institutes.

What Is The Infectious Disease Molecular Diagnostics Market Growth Forecast?

The infectious disease molecular diagnostics market size is expected to see steady growth in the next few years. It will grow to $38.77 billion in 2030 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to growing adoption of ai-driven diagnostic tools, rise in demand for rapid and accurate diagnostics, expansion of emerging markets healthcare infrastructure, increasing focus on personalized medicine, growth of home-based molecular diagnostic solutions. Major trends in the forecast period include rapid point-of-care diagnostic adoption, rising demand for multiplex testing, integration of molecular diagnostics with ehr systems, expansion of infectious disease surveillance programs, increasing focus on antimicrobial resistance detection.

Global Infectious Disease Molecular Diagnostics Market Segmentation

1) By Product Type: Kits And Reagents, Instruments, Software And Services 2) By Technology: Polymerase Chain Reaction, In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology, Chips And Microarrays, Sequencing-Based Molecular Diagnostics, Transcription Mediated Amplification, Other Technologies 3) By Application: Respiratory Diseases, Tuberculosis, Meningitis, Gastrointestinal Tract Infections, Human Papillomavirus, Sexually Transmitted Infections, Sepsis, Drug Resistance Diseases, Other Applications 4) By End-User: Hospitals And Clinical Laboratories, Diagnostic Laboratories, Pharmaceutical Companies, Academic And Research Institutes Subsegments: 1) By Kits And Reagents: Deoxyribonucleic Acid Or Ribonucleic Acid Extraction Kits, Polymerase Chain Reaction Reagents, Isothermal Amplification Kits, Probe-Based Detection Reagents, Pathogen-Specific Assay Kits 2) By Instruments: Real-Time Polymerase Chain Reaction Systems, Isothermal Amplification Instruments, Automated Sample Preparation Systems, Next-Generation Sequencing Platforms, Microarray Analyzers 3) By Software And Services: Data Analysis And Interpretation Software, Laboratory Information Management Systems, Cloud-Based Infectious Disease Diagnostic Platforms, Instrument Integration And Workflow Management Tools, Bioinformatics Services

What Is The Driver Of The Infectious Disease Molecular Diagnostics Market?

The increasing prevalence of infectious diseases is expected to propel the growth of the infectious disease molecular diagnostics market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites that can be spread directly or indirectly from one person to another. The rising prevalence of infectious diseases is primarily due to globalization and increased travel, allowing pathogens to spread rapidly across borders and turn localized outbreaks into global health emergencies. Infectious disease molecular diagnostics support infectious disease management by enabling rapid, accurate detection of pathogens at the genetic level, which facilitates early diagnosis, targeted treatment, and effective outbreak control. For instance, in November 2024, according to the US Centers for Disease Control and Prevention (CDC), a US-based government agency, tuberculosis (TB) cases in 2023 reached 9,633, up from 8,332 in 2022 marking a 15.6% increase in case count. Therefore, the increasing prevalence of infectious diseases is driving the growth of the infectious disease molecular diagnostics industry.

Key Players In The Global Infectious Disease Molecular Diagnostics Market

Major companies operating in the infectious disease molecular diagnostics market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company (BD), Agilent Technologies Inc., Hologic Inc., Illumina Inc., Biomerieux S.A., Quidel‑Ortho Corporation, Sysmex Corporation, Bio‑Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A., Seegene Inc., Oxford Nanopore Technologies plc, Biocartis NV, T2 Biosystems Inc., Sherlock Biosciences Inc.

Global Infectious Disease Molecular Diagnostics Market Trends and Insights

Major companies operating in the infectious disease molecular diagnostics market are focusing on developing innovative solutions, such as real-time polymerase chain reaction kits, to enable rapid, accurate, and high-throughput detection of infectious pathogens. Real-time polymerase chain reaction (PCR) kits are diagnostic tools that amplify and simultaneously detect specific genetic material of pathogens in real time, allowing for rapid and accurate identification of infectious diseases. For instance, in February 2023, Thermo Fisher Scientific Inc., a US-based biotechnology and life sciences company, launched Applied Biosystems TaqPath polymerase chain reaction kits designed for the detection of infectious diseases in India. These kits are fast, highly sensitive multiplex diagnostic solutions that enable real-time polymerase chain reaction detection of infectious disease targets using a complete workflow from ribonucleic acid extraction to diagnostic report generation, typically in under 4 hours. These kits feature multiplexed assays targeting multiple genomic regions of pathogens, include internal process controls, and provide automated data interpretation, reducing user error and enhancing result reliability.

What Are Latest Mergers And Acquisitions In The Infectious Disease Molecular Diagnostics Market?

In May 2024, Bruker Corporation, a US-based scientific instrument and analytical technology company, acquired ELITechGroup for $0.94 billion. With this acquisition, Bruker Corporation aims to strengthen its position as a specialist in infectious disease diagnostics by gaining access to modern sample-to-answer molecular diagnostic systems and a broad infectious disease assay portfolio that complements its existing products. ELITechGroup SAS is a France-based company that specializes in infectious disease molecular diagnostics.

Regional Outlook

North America was the largest region in the infectious disease molecular diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Infectious Disease Molecular Diagnostics Market?

The infectious disease molecular diagnostics market consists of revenues earned by entities by providing services such as polymerase chain Reaction (PCR) testing, next-generation sequencing, isothermal nucleic acid amplification tests, point-of-care (POC) molecular testing, and viral load monitoring and resistance testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The infectious disease molecular diagnostics market also includes sales of nucleic acid extraction systems, isothermal amplification assays, multiplex diagnostic panels, molecular diagnostic reagents and consumables, and bloodborne pathogen detection kits. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.